Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2) -positive breast cancer after prior HER2-directed therapy

Journal of Clinical Oncology

Volumn 29, Issue 4, 2011, Pages 398-405

  Burris III, Howard A ^a   Rugo, Hope S ^a   Vukelja, Svetislava J ^a   Vogel, Charles L ^a   Borson, Rachel A ^a   Limentani, Steven ^a   Tan Chiu, Elizabeth ^a   Krop, Ian E ^a   Michaelson, Richard A ^a   Girish, Sandhya ^a   Amler, Lukas ^a   Zheng, Maoxia ^a   Chu, Yu Waye ^a   Klencke, Barbara ^a   O'Shaughnessy, Joyce A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; TRASTUZUMAB DM1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HYPOKALEMIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAXIMUM PERMISSIBLE DOSE; METASTATIC BREAST CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTOXINS; KAPLAN-MEIER ESTIMATE; MAYTANSINE; MIDDLE AGED; RECEPTOR, ERBB-2; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 79952092706     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.5865     Document Type: Article

References (27)

1. Hynes NE, Stern DF: The biology of erbB-2/ neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165-184, 1994
2. Dawood S, Broglio K, Buzdar AU, et al: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol 28:92-98, 2010
3. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
4. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
5. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005 (Pubitemid 46207001)
6. Genentech: Trastuzumab (Herceptin®) investigator brochure. South San Francisco, CA, Genentech, 2007
7. Spector NL, Xia W, Burris H 3rd, et al: Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23:2502-2512, 2005 (Pubitemid 47050840)
8. Krop I, Beeram M, Modi S, et al: A phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28:2698-2704, 2010
9. Remillard S, Rebhun LI, Howie GA, et al: Antimitotic activity of the potent tumor inhibitor maytansine. Science 189:1002-1005, 1975
10. Cassady JM, Chan KK, Floss HG, et al: Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull 52:1-26, 2004 (Pubitemid 41685545)
11. Widdison WC, Wilhelm SD, Cavanagh EE, et al: Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49:4392-4408, 2006 (Pubitemid 44036683)
12. Lewis-Phillips GD, Li G, Dugger DL: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290, 2008
13. Junttila T, Fields C, Li G, et al: Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel. Presented at 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, October 21-24, 2008, Geneva, Switzerland
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
15. Makhija S, Amler LC, Glenn D, et al: Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 28:1215-1223, 2010
16. Cronin M, Pho M, Dutta D, et al: Measurement of gene expression in archival paraffin-embedded tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 164:35-42, 2004 (Pubitemid 38364587)
17. Ewer SM, Ewer MS: Cardiotoxicity profile of trastuzumab. Drug Saf 31:459-467, 2008 (Pubitemid 351695459)
18. Cabanillas F, Bodey GP, Burgess MA, et al: Results of a phase II study of maytansine in patients with breast carcinoma and melanoma. Cancer Treat Rep 63:507-509, 1979 (Pubitemid 9192260)
19. Chari RV, Martell BA, Gross JL, et al: Immunoconjugates containing novel maytansinoids: Promising anticancer drugs. Cancer Res 52:127-131, 1992
20. Erickson HK, Park PU, Widdison WC, et al: Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66:4426-4433, 2006
21. Burstein HJ, Sun Y, Dirix LY, et al: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28:1301-1307, 2010
22. Lee-Hoeflich ST, Crocker L, Yao E, et al: A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy. Cancer Res 68:5878-5887, 2008
23. Baselga J, Gelmon KA, Verma S, et al: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138-1144, 2010
24. Dalenc F, Campone M, Hupperets P, et al., Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial. J Clin Oncol 28:117s, 2010 (suppl 15S; abstr 1013)
25. Modi S, Stopeck AT, Gordon MS, et al: Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumabrefractory HER-2-overexpressing breast cancer: A phase I dose-escalation study. J Clin Oncol 25:5410-5417, 2007 (Pubitemid 350232217)
26. Press MF, Sauter G, Bernstein L, et al: Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11:6598-6607, 2005 (Pubitemid 41339000)
27. Krop I, LoRusso P, Miller KD, et al: A phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients previously treated with lapatinib, trastuzumab, and chemotherapy. 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009 (abstr 5091)